Anticoagulación para el tratamiento inicial de la tromboembolia venosa en personas con cáncer https://t.co/zahaC4ZACJ ✅La heparina de bajo peso molecular (HBPM) es probablemente superior a la HNF en el tratamiento inicial de la TEV en personas con cáncer.
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer - Kahale, LA - 2021 | Cochrane Library https://t.co/yIc8W5ihV9
Low molecular weight heparin (LMWH) is probably superior to UFH in the initial treatment of VTE in people with cancer @cochranecollab https://t.co/fVZGXV4pEt
RT @Charbel_matar1: ✅LMWH 💉is ⬆️ to UFH in the initial treatment of #VTE in people with #cancer 🩸2021 @CochraneLibrary @ASH_hematology @la…
RT @Charbel_matar1: ✅LMWH 💉is ⬆️ to UFH in the initial treatment of #VTE in people with #cancer 🩸2021 @CochraneLibrary @ASH_hematology @la…
✅LMWH 💉is ⬆️ to UFH in the initial treatment of #VTE in people with #cancer 🩸2021 @CochraneLibrary @ASH_hematology @larakahale @Elie__Akl @maram_hak @ITerrenato @schunemann_mac https://t.co/RCwxgriKKb